We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.

Pipeline Chart

※ As of Oct 2020

3 ADCs

  • DS-8201
  • U3-1402
  • DS-1062

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer

  • : Breakthrough Designation (US), SAKIGAKE Designation (JP)
  • : Orphan drug designation (JP/US/EU)

Phase 1

  • DS-8201 (US/EU)
    BC, bladder cancer (nivolumab combo)
  • DS-8201 (US/EU)
    BC, NSCLC (pembrolizumab combo)
  • DS-8201 (US/EU/Asia)
    HER2+ GC combo 2L~/1L
    DESTINY-Gastric03
  • U3-1402 (JP/US)
    HER3+BC
  • U3-1402 (JP/US/EU/Asia)
    NSCLC
  • DS-1062 (JP/US)
    NSCLC, TNBC
  • DS-1062 (JP/US)
    NSCLC (without actionable mutation, pembrolizumab combo)
    TROPION-Lung02

Phase 2

  • DS-8201 (JP/US/EU)
    HER2+/m NSCLC
    DESTINY-Lung01
  • DS-8201 (JP/US/EU)
    HER2+ CRC
    DESTINY-CRC01
  • DS-8201 (US/EU)
    HER2+ GC 2L
    DESTINY-Gastric02
  • DS-8201 (US/EU/Asia)
    NSCLC (durvalumab combo)
    HUDSON
  • DS-8201 (US/EU/Asia)
    TNBC (with durvalumab)
    BEGONIA
  • DS-8201 (US/Asia) 
    HER2 expressing tumors
    DESTINY-PanTumor02
  • U3-1402 (JP/US/EU)
    HER3 CRC

Phase 3

  • DS-8201 (JP/US/EU/Asia)
    HER2+BC 3L
    DESTINY-Breast02
  • DS-8201 (JP/US/EU/Asia)
    HER2+BC 2L
    DESTINY-Breast03
  • DS-8201 (JP/US/EU/Asia)
    HER2 low BC 3L~
    DESTINY-Breast04
  • DS-8201 (US/EU/Asia)
    HER2 low BC chemo naive
    DESTINY-Breast06

Submitted

  • DS-8201 (US)
    HER2+GC 3L
    DESTINY-Gastric01
  • DS-8201 (EU)
    HER2+BC 3L
    DESTINY-Breast01

Alpha

  • Oncology
  • Specialty Medicines
  • Vaccine

AF: atrial fibrillation, ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, DMD: Duchenne muscular dystrophy, GIST: gastrointestinal stromal tumor, IIS: investigator-initiated study, NSCLC: non-small cell lung cancer, PTCL: peripheral T-cell lymphoma

  • : Project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
  • : SAKIGAKE Designation (JP)
  • : Orphan drug designation (JP/US/EU)

Phase 1

  • DS-3201 (JP/US)
    EZH1/2 inhibitor
    Non-Hodgkin‘s Lymphomas (PTCL)
  • DS-3201 (US)
    EZH1/2 inhibitor
    AML, ALL
  • PLX2853 (US)
    BET inhibitor
    AML
  • PLX2853 (US)
    BET inhibitor
    Solid tumors
  • DS-1211 (US)
    TNAP inhibitor
    Pseudoxanthoma elasticum
  • DS-7300 (JP/US)
    B7-H3-directed ADC
    Solid tumors
  • DS-6157 (JP/US)
    GPR20-directed ADC
    GIST
  • DS-1055 (JP/US)
    Anti-GARP antibody
    Solid turmors
  • DS-2741 (JP)
    Anti-Orai1 antibody
    Atopic dermatitis

Phase 2

  • DS-1647 (G47Δ) (JP)
    Oncolytic HSV-1
    Malignant glioma
    IIS
  • DS-3201 (JP)
    EZH1/2 inhibitor
    ATL/L
  • DS-1001 (JP)
    Mutant IDH1 inhibitor
    Glioma
  • DS-5141 (JP)
    ENA oligonucleotide
    DMD

Phase 3

  • Quizartinib (JP/US/EU/Asia)
    FLT3 inhibitor
    1L AML
  • Prasugrel (JP)
    ADP receptor inhibitor
    Ischemic stroke
  • Mirogabalin (JP/Asia)
    α2δ Ligands
    Central neuropathic pain
  • Esaxerenone (JP)
    MR blocker
    Diabetic nephropathy
  • VN-0102/JVC-001 (JP)
    Measles mumps rubella
    combined vaccine

Submitted

  • Axicabtagene ciloleucel
    Axi-Cel™
    (JP)
    Anti CD19 CAR-T cells
    R/R B-cell lymphoma
  • VN-0107/MEDI3250 (JP)
    Live attenuated influenza vaccine nasal spray
  • Edoxaban (JP)
    FXa inhibitor
    AF in the very elderly